Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaumont-Gistoux – page 129

1 874 clinical trials in Chaumont-Gistoux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaumont-Gistoux at a glance
1 874
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 874 trials in Chaumont-Gistoux

Open in trial search

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Neoplasm

Not recruiting

Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm malignant

Not recruiting

Study for Patients with cMET-Dependent Cancers to Continue Treatment with Capmatinib, Nazartinib, and Gefitinib

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capmatinib
  • Sponsor:Novartis Pharma AG

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study of Gilteritinib and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Astellas Pharma Global Development Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Malignant melanoma+1

Not recruiting

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Naporafenib
  • Sponsor:Novartis Pharma AG

Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ceritinib
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaumont-Gistoux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The study explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment protocols for long-term digestive health management.

02 Digestive Health Studies

Research examining the effectiveness of different management strategies for heartburn and reflux symptoms. The trials evaluate various therapeutic approaches, including alginate formulations as alternative treatments.

  • Symptom Management
  • Treatment Optimization
  • Patient-Centered Care

These investigations aim to improve quality of life for patients while identifying more targeted and efficient treatment strategies.

03 Primary Care Innovation

Forward-thinking research in primary care settings focusing on medication optimization and patient-centered approaches to chronic condition management.

  • Medication Management
  • Evidence-Based Protocols
  • Clinical Practice Enhancement

This research aims to establish better guidelines for long-term medication management in primary care practices.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.